Zhang Xiaoli, Yu Jinming, Zhu Hui, Meng Xue, Li Minghuan, Jiang Liyang, Ding Xingchen, Sun Xindong
. Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
. Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, Jinan, China.
Oncotarget. 2017 Mar 28;8(13):22251-22261. doi: 10.18632/oncotarget.14759.
Extensive stage small cell lung cancer (ES-SCLC) represents approximately half of all diagnosed small cell lung cancer worldwide. It is notorious for a high risk of local recurrence although it's sensitive to chemotherapy. Nearly 90% of intrathoracic failures happen in the first year after diagnosis. The cornerstone of treatment for ES-SCLC is etoposide-platinum based chemotherapy. Consolidative radiotherapy to thorax has diminished the incidence of local relapse, therefore it should be offered to patients with excellent response to induction first-line chemotherapy. This review centers on the clinical evidence for the use of thoracic radiotherapy (TRT) and current modalities of TRT delivery, then tries to determine a feasible way to conduct TRT in a selective group of cases.
广泛期小细胞肺癌（ES-SCLC）约占全球所有确诊小细胞肺癌的一半。尽管它对化疗敏感，但因其局部复发风险高而声名狼藉。近90%的胸内复发发生在诊断后的第一年。ES-SCLC治疗的基石是以依托泊苷-铂类为基础的化疗。胸部巩固放疗降低了局部复发的发生率，因此应首先提供给诱导一线化疗反应良好的患者。本综述聚焦于胸部放疗（TRT）应用的临床证据及当前TRT的实施方式，然后试图确定在一组特定病例中进行TRT的可行方法。
